- Entire Pipeline
- Discovery & Early Development
- Pre-clinical & Clinical Development
- Limited Market Availability
Displaying 121 - 130 of 243
Alternative Name: Levonorgestrel Gastric Resident Dosage Form, Levonorgestrel Gastric Retentive Dosage Form
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Lyndra Therapeutics, Massachusetts Institute of Technology
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Levonorgestrel (LNG) Intracervical Device (ICD)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal, Other
Developer: University of Helsinki, Population Council
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Levonorgestrel (LNG)-only patch; AG890
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Agile Therapeutics
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: One-year LNG Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: CONRAD, FEI Technologies
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: Orbis Biosciences
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: FHI 360
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: (3β,13ξ)-Lup-20(29)-en-3-ol; Clerodol; Monogynol B; Fagarasterol; Farganasterol
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Oral, Other
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Merck
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Emergency
Delivery Method: Oral
Developer: CONRAD
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Delivery Method: Vaginal Ring
Developer: Andromaco
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Pages
Displaying 61 - 70 of 70
User: Female
Hormonal: No
Developer: Rutgers University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Target
User: Male
Hormonal: No
Developer: Baylor College of Medicine, NICHD
Development Stage: Target Validation
Alternative Name: RISUG in the Fallopian Tube
User: Female
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Fallopian Tube
Developer: Indian Institute of Technology, Kharagpur
Development Stage: Prototype Development
Alternative Name: Tripterygium wilfordii derivatives, including triptolide
User: Male
Hormonal: No
Developer: WHO, University of California at Los Angeles
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: FHI 360, GE Healthcare
Development Stage: Prototype Development
User: Female
Hormonal: Yes
Delivery Method: Vaginal, Other
Developer: University of Texas Health Science Center at San Antonio
Development Stage: Lead Optimization
Alternative Name: WEE1 HOMOLOG 2; WEE1B; WEE2 Kinase
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Lead Optimization
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization
Pages
Displaying 21 - 30 of 121
Alternative Name: DVD2
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: FHI 360
Development Stage: Phase I
Alternative Name: DMAU
User: Male
Hormonal: Yes
Duration Type: Short-acting
Developer: BIOQUAL, Inc., NICHD, University of California at Los Angeles
Development Stage: Phase I
Alternative Name: Depot Medroxyprogesterone Acetate (DMPA) + Testosterone
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: ANZAC Research Institute
Development Stage: Phase I
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: National Research Institute for Family Planning in Beijing
Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: International Partnership for Microbicides, USAID
Development Stage: Phase I
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier, Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Viramal Limited
Development Stage: Pre-clinical
Alternative Name: Merck Vaginal Ring MK-8342B
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Phase III
Alternative Name: Casea S
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360
Development Stage: Phase I
Pages
Displaying 21 - 30 of 52
Alternative Name: GyneFix 330
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shenyang Liren Medical & Technological Co.
Development Stage: Marketed
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved
Pages
